Deciding on thrombolytic therapy in pulmonary embolism -is there room for lactate
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INTRODUCTION
Pulmonary embolism (PE) is a condition with many non-specific symptoms, which is the reason why even today PE is largely underdiagnosed and the correct diagnosis is unfortunately often made post mortem [1] . Incidence of PE is high -among cardiovascular diseases, it is in the third place, right after myocardial infarction and cerebrovascular insult [2] . Even with all the current guidelines for prevention, diagnostics, and therapy, PE is a very common cause of death not only in outpatients, but also in hospitalized patients [3, 4] . The current guidelines state that determining clinical probability of PE is a conditio sine qua non in a diagnostic algorithm [3, 4] . Further diagnostic steps depend on the determined level of clinical probability for PE. Further stratification of patients is used to define early mortality risk within 30 days of diagnosing PE. Criteria used for this stratification include hemodynamic stability, Pulmonary Embolism Severity Index (PESI) ( Table 1) , signs of right ventricular dysfunction and elevated cardiac biomarkers (troponin T or I, NT proBNP -brain natriuretic peptide) (Table 2) [4, 5] . The main criterion when it comes to the choice between anticoagulant therapy versus thrombolytic therapy is the presence of shock, that is hemodynamic instability [4] This decision is often a big challenge in everyday clinical practice, and that is why we chose this particular case to illustrate clinical dilemmas in a difficult decision whether to apply thrombolytic therapy.
CASE REPORT
The patient was a 56-year-old female who was referred to the Institute of Pulmonary Diseases of Vojvodina for suspected PE. Her symptoms included pain in her right shoulder and pain she localised in the right hypochondrium, along with the loss of appetite, followed by weight loss of more than 10 kg during the previous month. The patient's previous medical history showed that she had been diagnosed with bronchiectasis five years earlier, which was the cause of several previous hospitalizations at the Institute. At admission, the patient was afebrile, eupneic, normocardic, normotensive, and late inspiratory crackles were audible over both lung bases. Electrocardiogram showed incomplete right bundle branch block, sinus rhythm at 80 beats per minute. Blood gas analysis showed severe type I respiratory insufficiency with the signs of hyperventilation (PaO 2 5.76 kPa, PaCO 2 4.12 kPa, pH 7.4, SaO 2 78.5%). Chest X-ray ( Figure 1 ) showed bilateral patchy infiltrates in lower lung fields, blunted right FC sinus, and enlarged cardiac silhouette. According to the Wells scoring system (Table 3) , the patient was classified as low clinical probability for PE (Wells 0) [6] . American Chest Physicians Association recommends that patients with low clinical probability for PE should be tested for the Pulmonary Embolism Rule-out Criteria (PERC) ( Table 4 ) [3, 7] . Since our patient did not meet the PERC criteria (older than 50 and SpO 2 lower than 95%), the cited guidelines recommend testing for D dimer, which was in this case extremely elevated (7,000 ng/ml). The next and final diagnostic step was computerized tomographic pulmonary angiography (CTPA), which confirmed PE in our patient: there were filling defects in the distal part of the right pulmonary artery as well as in the middle lobe branch and eight segment branch, along with suspected thrombi in peripheral branches for the left lower lobe, and bilateral bronchiectasis (Figures 2a and 2b ). Quanadli index of pulmonary obstruction was 19.5% [8] . Laboratory findings included increased white blood cell count (15 × 10 9 /l), C-reactive protein was moderately increased with normal procalcitonin level and elevated serum lactate (2.46 mmol/l). NT pro BNP was also significantly elevated -15,000 ng/ml. Echocardiography verified signs of chronic pulmonary hypertension with suspected acutization: enlarged right atrium and ventricle, with the ratio of end-diastolic diameter of the right ventricle to the left ventricle of > 0.9, free right ventricular wall was hypokinetic, with decreased tricuspid annular plane systolic excursion of 8 mm, which is an indicator of global right ventricular dysfunction. There was a moderate degree of pulmonary hypertension (RVSP-RV systolic pressure of 65 mmHg), mainly explained by presence of chronic pulmonary commorbidities (bronchiectasis and chronic respiratory insufficiency). Pulmonary artery acceleration time was 70 milliseconds. The inferior vena cava was dilated and barely collapsible during the inspirium. Ejection fraction of the left ventricle was preserved (60%).
Prognosis wise, and calculated according to the simplified PESI index (Simplified Pulmonary Embolism Severity Index -sPESI) (Table 3) , the patient had a 10.9% risk for early mortality [9] . Furthermore, since her sPESI index was ≥ 1 and due to the fact that she also had echocardiographic signs of right ventricular dysfunction along with positive cardiac biomarkers, this patient was classified as high intermediate risk for early mortality, in line with the European Society of Cardiology guidelines [4] . Therapy recommendations for these patients imply anticoagulant therapy, with continuous monitoring of their vital parameters. Thrombolytic therapy within this group is recommended only if hemodynamic instability ensues. Our patient was diagnosed and treated in accordance with all the cited guidelines -she was admitted to the High Dependency Unit, where she was continuously non-invasively monitored and received parenteral heparin therapy. However, six hours upon admission, she developed hemodynamic instability and was immediately transferred to the Intensive Care Unit (ICU). Her initial APACHE II score was 20 (PDR 35.5, adjusted 32.6). She then received thrombolytic therapy (streptokinase) according to the rapid protocol. After 72 hours, there was a recurrent PE, and the intensivists repeated thrombolytic therapy. During the further clinical course, she had to be intubated, and due to the necessity for prolonged ventilatory support, percutaneous tracheostomy was performed. After five days in the ICU, she was stabilized and afterwards transferred to the general ward. Oral anticoagulant therapy was titrated and she was discharged from hospital on day 30.
DISCUSSION
Some conclusions can be drawn from this report; yet, several everyday clinical dilemmas illustrated by this clinical scenario remain.
Firstly, the patient was categorized as having low clinical probability for PE (Wells 0). However, since she met two PERC criteria, PE could not be ruled out without D-dimer. The patient's D-dimer was extremely elevated, which preconditioned the final diagnostic step -CTPA. Also, echocardiographic findings were interpreted as chronic pulmonary hypertension with suspected signs of acutization. Since the patient had a pre-existing lung disease (bronchiectasis, respiratory insufficiency), which probably led to chronic pulmonary hypertension, this was an additional diagnostic dilemma.
Another moot point is appropriate therapy in patients with confirmed PE, who are categorized as having intermediate high risk of early mortality, such as our patient. Many patients in this group do well on anticoagulant therapy only; however, there are a few cases were hemodynamic instability develops during parenteral anticoagulant therapy, which then necessitates thrombolytics. This is the reason the patients in this subgroup must be carefully monitored in order to timely recognize clinical deterioration. Research in this field has not been conclusive thus far -further studies are needed to confirm true predictors of early mortality, which would be included in a satisfactory prognostic model [10, 11, 12] . Current research results show that patients with PE who initially had increased lactate levels had significantly higher mortality (17.3% vs. 1.6%) [11] . Bova et al. [12] conducted research on patients with intermediate high mortality risk and showed that the combination of cardiac biomarkers, echocardiographic signs of right ventricular dysfunction, tachycardia, and hypotension increased the risk of complications during the initial 30 days as much as seven-fold. The Thromboembolism Lactate Outcome Study (TELOS) in normotensive patients with PE revealed that this group of patients, if they had right ventricular dysfunction, elevated troponin and elevated plasma lactate are considered intermediate-high risk, and this patient had significantly more PE-related complications. Recent studies which compared the European Society of Cardiology, Bova and TELOS models for more accurately identifying patients with PE and intermediate high risk concluded that adding plasma lactate to the Bova score was a significantly powerful model [13, 14] .
In conclusion, although our patient was initially stable on anticoagulant therapy, there were two episodes of hemodynamic instability during the first 72 hours, which significantly increased her mortality risk. Our dilemma remains: since she had increased lactate levels at the very beginning, indicating poor perfusion despite normal blood pressure, should have we administered thrombolytic therapy earlier? American College of Chest Physicians suggests that broader criteria for true hemodynamic instability should be considered in these patients, including hypotension, tachycardia, distended jugular veins, clinical signs of poor tissue perfusion, and hypoxemia, but further studies are warranted [15] . 
САЖЕТАК
Увод Дијагностички и терапијски алгоритам за плућну ем-болију (ПЕ) више пута се мењао, али је увек први корак у постављању дијагнозе одређивање степена клиничке ве-роватноће постојања ПЕ, што условљава даље процедуре. Циљ је био да се илуструје терапијска дилема код болес-нице са интермедијарно високим ризиком за 30-дневни морталитет. Приказ болесника Болесница стара 56 година упућена је у нашу институцију са сумњом на ПЕ. Према Велсовом бо-довном систему припадала је групи са малом клиничком вероватноћом постојања ПЕ, а применом препоручених критеријума групи болесника са интермедијарно високим ризиком за смртни исход у наредних 30 дана. ПЕ је по-тврђена КТ-ангиографијом. Примењена је, према препо-рукама, иницијално хепаринска терапија, а због настанка хемодинамске нестабилности у даљем току и тромболи-тичка терапија, са позитивним исходом. Код болеснице је иницијално у биохуморалном статусу био повишен маркер ткивне хипоперфузије -лактат, који се не ради рутински код болесника са ПЕ. Закључак Код болесника са средње високим ризиком од смртног исхода у року од 30 дана од настанка болести акту-елна је препорука да се лечење започне хепарином, а да се сталним мониторингом на време препознају знаци хемоди-намске нестабилности и пропише тромболитична терапија. У приказаном случају тромболитичка терапија је прописана тек по развоју хемодинамске нестабилности, упркос прет-ходно присутним раним знацима ткивне хипоперфузије. 
